Article Sidebar
Published:
Feb 18, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Eriocalyxin B relieves kidney damage in a rat model of membranous nephropathy by inhibiting JAK/STAT3 pathway
Abstract
Purpose: To investigate the function of eriocalyxin B (EriB) in membranous nephropathy (MN) in a rat model and the related mechanisms.
Methods: Cationic C-BSA was injected into Sprague-Dawley (SD) rats to generate a rat model of MN. The MN rats were treated with different concentrations of EriB (2.5, 5, and 10 mg/kg). After treatment, their kidneys were excised, sectioned, and hematoxylin and eosin (H&E) stained to determine renal injury, while Masson's trichrome staining was performed to determine renal tissue fibrosis. Bradford assay was used to determine rat proteinuria and ELISA employed to determine blood urea nitrogen (BUN) and serum creatinine (SCr) levels. ELISA was also used to measure IL-1β, IL-6, and TGF-α levels, while immunoblot analysis was used to assess protein expressions of related indicators in JAK/STAT3 pathway.
Results: Compared with sham rats, MN rats showed increased the contents of proteinuria, BUN, and SCr (p < 0.01), induced serious renal injury, and increased expression of collagen I and III (p < 0.01), and fibrosis. It also elevated the levels of IL-1β, IL-6, and TGF-α (p < 0.01), causing inflammation and activation of the JAK/STAT3 pathway. EriB treatment alleviated renal injury, fibrosis, and inflammation in MN rats. With increase in EriB concentration, renal injury in MN rats was gradually alleviated.
Conclusion: EriB alleviates renal injury in MN rats by inhibiting JAK/STAT3 pathway. Thus, EriB is a potential drug for the management of MN.
